A better way of delivering drugs for acute myeloid leukaemia
Testing nanoparticles as a way of getting drugs where they are needed for acute myeloid leukaemia.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Testing nanoparticles as a way of getting drugs where they are needed for acute myeloid leukaemia.
Stopping protein activity to stop anaplastic large cell lymphomas from growing.
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.
Developing better models of rhabdomyosarcoma to test available treatments.
Developing more effective treatments for patients who have a low chance of survival, while reducing treatment and side effects for other patients.
Our proposal will deliver novel, less toxic targeted therapies with the potential to advance current treatment regimens for B-ALL. This will improve current outcomes, reduce side-effects in B-ALL patients and ultimately lead to a better quality of life for patients and their families.
Ewing sarcoma is the second most common bone tumour in young people. The primary goal of this project is to fast-track a targeted drug combination for evaluation in clinical trials, with the aim of improving outcomes and minimising treatment associated morbidities for Ewing sarcoma patients.
Investigating a new method to improve the success of bone marrow transplants, using a different type of blood cells.